<!DOCTYPE html>
<html lang="zh-CN">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=5.0">
    <title>ç§‘ç ”æ—¥æŠ¥ - 2026-01-18</title>
    <style>
        * {
            margin: 0;
            padding: 0;
            box-sizing: border-box;
        }

        body {
            font-family: -apple-system, BlinkMacSystemFont, "Segoe UI", Roboto, "Helvetica Neue", Arial, "Noto Sans", sans-serif, "Apple Color Emoji", "Segoe UI Emoji";
            line-height: 1.8;
            color: #2c3e50;
            background: linear-gradient(135deg, #f5f7fa 0%, #c3cfe2 100%);
            padding: 15px;
            font-size: 16px;
        }

        .container {
            max-width: 900px;
            margin: 0 auto;
            background: white;
            padding: 35px;
            border-radius: 16px;
            box-shadow: 0 10px 40px rgba(0,0,0,0.1);
        }

        /* æ ‡é¢˜ä¼˜åŒ– */
        h1 {
            color: #1a202c;
            font-size: 2em;
            border-bottom: 4px solid #667eea;
            padding-bottom: 15px;
            margin-bottom: 25px;
            font-weight: 700;
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            -webkit-background-clip: text;
            -webkit-text-fill-color: transparent;
            background-clip: text;
        }

        h2 {
            color: #2d3748;
            font-size: 1.5em;
            margin-top: 40px;
            margin-bottom: 20px;
            padding-left: 15px;
            border-left: 5px solid #667eea;
            font-weight: 600;
        }

        h3 {
            color: #4a5568;
            font-size: 1.25em;
            margin-top: 28px;
            margin-bottom: 14px;
            font-weight: 600;
        }

        /* åˆ†ç±»æµè§ˆæŠ˜å åŠŸèƒ½ */
        details {
            margin: 20px 0;
            border-radius: 8px;
            overflow: hidden;
        }

        details summary {
            cursor: pointer;
            padding: 15px 20px;
            background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%);
            color: #2d3748;
            font-size: 1.25em;
            font-weight: 600;
            text-align: right;
            direction: rtl;
            border-right: 5px solid #667eea;
            transition: all 0.3s ease;
            list-style: none;
            user-select: none;
        }

        details summary * {
            direction: ltr;
        }

        details summary::-webkit-details-marker {
            display: none;
        }

        details summary::before {
            content: 'â–¶';
            display: inline-block;
            margin-left: 10px;
            transition: transform 0.3s ease;
            font-size: 0.8em;
        }

        details[open] summary::before {
            transform: rotate(90deg);
        }

        details summary:hover {
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            color: white;
            box-shadow: 0 4px 12px rgba(102, 126, 234, 0.3);
        }

        details[open] summary {
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            color: white;
            border-right-color: white;
        }

        details .details-content {
            padding: 20px;
            background: white;
            border: 1px solid #e9ecef;
            border-top: none;
        }

        h4 {
            color: #718096;
            font-size: 1.1em;
            margin-top: 22px;
            margin-bottom: 12px;
            font-weight: 600;
        }

        p {
            margin-bottom: 16px;
            line-height: 1.8;
        }

        blockquote {
            background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%);
            border-left: 4px solid #667eea;
            padding: 18px 22px;
            margin: 22px 0;
            border-radius: 8px;
            color: #4a5568;
            font-size: 0.95em;
            box-shadow: 0 2px 8px rgba(0,0,0,0.05);
        }

        blockquote p {
            margin-bottom: 8px;
        }

        blockquote p:last-child {
            margin-bottom: 0;
        }

        blockquote em {
            font-style: normal;
            color: #718096;
            font-size: 0.9em;
        }

        blockquote a {
            color: #667eea;
            font-weight: 500;
            border-bottom: 1px solid rgba(102, 126, 234, 0.3);
        }

        blockquote a:hover {
            color: #764ba2;
            border-bottom-color: #764ba2;
        }

        /* é¡¶éƒ¨ç½²åï¼ˆå±…å³ï¼‰ */
        .powered-by-top {
            text-align: right;
            font-size: 0.85em;
            color: #718096;
            font-style: italic;
            margin: 12px 0;
            padding-right: 5px;
        }

        .powered-by-top a {
            color: #667eea;
            font-weight: 500;
            border-bottom: 1px solid rgba(102, 126, 234, 0.3);
        }

        .powered-by-top a:hover {
            color: #764ba2;
            border-bottom-color: #764ba2;
        }

        /* AI æ€»ç»“åŒºåŸŸä¼˜åŒ– */
        .ai-summary {
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            color: white;
            padding: 28px;
            border-radius: 16px;
            margin: 30px 0;
            box-shadow: 0 12px 35px rgba(102, 126, 234, 0.35);
            position: relative;
            overflow: hidden;
        }

        .ai-summary::before {
            content: '';
            position: absolute;
            top: -50%;
            right: -50%;
            width: 200%;
            height: 200%;
            background: radial-gradient(circle, rgba(255,255,255,0.1) 0%, transparent 70%);
            pointer-events: none;
        }

        .ai-summary h2 {
            color: white;
            border-left: none;
            border-right: none;
            margin-top: 0;
            margin-bottom: 18px;
            padding-left: 15px;
            padding-right: 0;
            text-align: left;
            direction: ltr;
        }

        .ai-summary h3 {
            color: #f0f0f0;
            margin-top: 18px;
            border-right: 3px solid rgba(255,255,255,0.5);
            padding-right: 12px;
            padding-left: 0;
            text-align: right;
            direction: rtl;
        }

        .ai-summary h3 * {
            direction: ltr;
        }

        .ai-summary blockquote {
            background: rgba(255,255,255,0.15);
            border-left-color: white;
            color: white;
            backdrop-filter: blur(10px);
        }

        .ai-summary p {
            color: white;
        }

        .ai-summary strong {
            color: #fff;
            font-weight: 600;
        }

        ul, ol {
            margin-left: 28px;
            margin-bottom: 18px;
        }

        li {
            margin-bottom: 12px;
            line-height: 1.8;
        }

        /* é“¾æ¥ä¼˜åŒ– */
        a {
            color: #667eea;
            text-decoration: none;
            border-bottom: 1px solid transparent;
            transition: all 0.3s ease;
            font-weight: 500;
        }

        a:hover {
            border-bottom-color: #667eea;
            color: #764ba2;
        }

        /* è¡¨æ ¼ä¼˜åŒ– */
        table {
            width: 100%;
            border-collapse: collapse;
            margin: 20px 0;
            box-shadow: 0 2px 12px rgba(0,0,0,0.08);
            border-radius: 10px;
            overflow: hidden;
        }

        th, td {
            border: 1px solid #e2e8f0;
            padding: 14px 18px;
            text-align: left;
        }

        th {
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            color: white;
            font-weight: 600;
            font-size: 0.95em;
        }

        tr:nth-child(even) {
            background: #f8f9fa;
        }

        tr:hover {
            background: #e9ecef;
            transition: background 0.3s ease;
        }

        /* å…³é”®è¯ç»Ÿè®¡è¡¨æ ¼ç‰¹æ®Šæ ·å¼ï¼ˆæ›´ç´§å‡‘ï¼‰ */
        .keywords-table {
            font-size: 0.9em;
            max-width: 600px;
        }

        .keywords-table th,
        .keywords-table td {
            padding: 10px 14px;
        }

        .keywords-table th {
            font-size: 0.9em;
        }

        hr {
            border: none;
            border-top: 2px solid #e2e8f0;
            margin: 40px 0;
        }

        strong {
            color: #2d3748;
            font-weight: 600;
        }

        code {
            background: #f1f5f9;
            padding: 3px 8px;
            border-radius: 5px;
            font-family: "SF Mono", Monaco, Consolas, "Courier New", monospace;
            font-size: 0.9em;
            color: #e53e3e;
        }

        /* ç¾åŒ–æ»šåŠ¨æ¡ */
        ::-webkit-scrollbar {
            width: 8px;
            height: 8px;
        }

        ::-webkit-scrollbar-track {
            background: #f1f1f1;
            border-radius: 4px;
        }

        ::-webkit-scrollbar-thumb {
            background: #667eea;
            border-radius: 4px;
        }

        ::-webkit-scrollbar-thumb:hover {
            background: #764ba2;
        }

        /* ç§»åŠ¨ç«¯ä¼˜åŒ– */
        @media (max-width: 768px) {
            body {
                padding: 8px;
                font-size: 15px;
            }

            .container {
                padding: 22px 18px;
                border-radius: 12px;
            }

            h1 {
                font-size: 1.6em;
                padding-bottom: 12px;
                margin-bottom: 20px;
            }

            h2 {
                font-size: 1.3em;
                margin-top: 30px;
                padding-left: 12px;
            }

            h3 {
                font-size: 1.15em;
            }

            h4 {
                font-size: 1.05em;
            }

            blockquote {
                padding: 14px 16px;
                margin: 18px 0;
            }

            .ai-summary {
                padding: 20px;
                margin: 22px 0;
            }

            .ai-summary-header {
                flex-direction: column;
                align-items: flex-start;
            }

            .powered-by {
                margin-left: 0;
                margin-top: 8px;
            }

            table {
                font-size: 0.85em;
            }

            th, td {
                padding: 10px 12px;
            }

            .keywords-table {
                font-size: 0.8em;
            }

            .keywords-table th,
            .keywords-table td {
                padding: 8px 10px;
            }

            ul, ol {
                margin-left: 22px;
            }
        }

        /* è¶…å°å±å¹• */
        @media (max-width: 480px) {
            body {
                font-size: 14px;
                padding: 5px;
            }

            .container {
                padding: 18px 14px;
            }

            h1 {
                font-size: 1.4em;
            }

            h2 {
                font-size: 1.2em;
            }

            .ai-summary {
                padding: 16px;
            }

            .powered-by {
                font-size: 0.7em;
            }
        }

        /* å¹³æ»‘æ»šåŠ¨ */
        html {
            scroll-behavior: smooth;
        }

        /* æé«˜å¯ç‚¹å‡»åŒºåŸŸ */
        @media (pointer: coarse) {
            a {
                padding: 4px 0;
                display: inline-block;
            }
        }

        /* æ‰“å°ä¼˜åŒ– */
        @media print {
            body {
                background: white;
                padding: 0;
            }

            .container {
                box-shadow: none;
                max-width: 100%;
            }

            .ai-summary {
                background: #f5f5f5;
                color: black;
                box-shadow: none;
            }

            .ai-summary h2,
            .ai-summary h3,
            .ai-summary p,
            .ai-summary strong {
                color: black;
            }
        }
    </style>
</head>
<body>
    <div class="container">
        <h1>ğŸ“… Daily Report - 2026-01-18</h1>
<blockquote>
<p>ä»Šæ—¥ç­›é€‰å‡º <strong>42</strong> æ¡å†…å®¹ï¼Œæ¥è‡ª <strong>2</strong> ä¸ªæ¥æº</p>
</blockquote>
<div class="powered-by-top">Powered by <a href="https://kyplus.de" target="_blank" rel="noopener noreferrer">ç§‘ç ”æ™®æ‹‰æ–¯</a> & <a href="https://claude.ai" target="_blank" rel="noopener noreferrer">Claude</a></div>

<hr />
<div class="ai-summary">
                <h2>ğŸ¤– ä»Šæ—¥AIæ™ºèƒ½æ€»ç»“</h2>
                <h3>ğŸ§¬ æ•°æ®å‰æ²¿</h3>
<blockquote>
<p><strong>ä»Šæ—¥ç„¦ç‚¹</strong>ï¼š<br />
* <strong>è‚¿ç˜¤å¾®ç¯å¢ƒé‡å¡‘æœºåˆ¶æ­ç¤º</strong>ï¼šå¤šé¡¹ç ”ç©¶èšç„¦æŸ“è‰²ä½“ä¸ç¨³å®šæ€§ï¼ˆCINï¼‰å¦‚ä½•é€šè¿‡cGAS-è¶‹åŒ–å› å­-é«“ç³»ç»†èƒè½´é‡å¡‘é£Ÿç®¡è…ºç™Œå¾®ç¯å¢ƒï¼Œä»¥åŠClaudinsä¸LILRBå…ç–«æŠ‘åˆ¶å—ä½“çš„ç›¸äº’ä½œç”¨ä¿ƒè¿›é«“ç³»ç»†èƒå…ç–«æŠ‘åˆ¶ã€‚</p>
</blockquote>
<p><strong>ä¸»è¦æ–¹å‘</strong>ï¼š<br />
* <strong>è‚¿ç˜¤è½¬ç§»ä¸å…ç–«è°ƒæ§</strong>ï¼šç ”ç©¶è‚¿ç˜¤ç»†èƒç°‡å¢å¼ºè½¬ç§»èƒ½åŠ›ï¼ˆè°ƒæ§H3K36ç»„è›‹ç™½å»ç”²åŸºåŒ–é…¶KDM2Aï¼‰ï¼ŒHMGB2ä½œä¸ºåŒé‡å…ç–«è°ƒèŠ‚å‰‚åœ¨è‚ç»†èƒç™Œä¸­å¢å¼ºCD8+ Tç»†èƒåŠŸèƒ½å¹¶æŠ‘åˆ¶è‚¿ç˜¤ç”Ÿé•¿ã€‚<br />
* <strong>Tç»†èƒåŠŸèƒ½ä¸åˆ†åŒ–</strong>ï¼šæ¢ç´¢Dnmt3aä¾èµ–çš„DNAå»ç”²åŸºåŒ–å¦‚ä½•ç»´æŒè®°å¿†Th1å’ŒTfhç»†èƒçš„åŠŸèƒ½ï¼Œä»¥åŠPD-1ç¼ºå¤±çš„CD8+ Tç»†èƒåœ¨æ…¢æ€§åˆºæ¿€ä¸‹çš„é€‚åº”æ€§æœºåˆ¶ã€‚<br />
* <strong>è‚¿ç˜¤è€è¯æ€§æœºåˆ¶</strong>ï¼šæ­ç¤ºAURKA/PHB2ä¿¡å·é€šè·¯é©±åŠ¨KRAS G12Cçªå˜éå°ç»†èƒè‚ºç™Œå¯¹KRAS G12CæŠ‘åˆ¶å‰‚è·å¾—æ€§è€è¯ã€‚</p>
<p><strong>æŠ€æœ¯äº®ç‚¹</strong>ï¼š<br />
* <strong>å•ç»†èƒæµ‹åºåº”ç”¨</strong>ï¼šå¹¿æ³›åº”ç”¨äºèƒ°è…ºå¯¼ç®¡è…ºç™Œï¼ˆPDAï¼‰ç»†èƒç³»ç ”ç©¶ï¼ŒåŒ…æ‹¬è¯ç‰©å¤„ç†å‰åã€ä»¥åŠç”¨äºè°±ç³»è¿½è¸ªã€‚<br />
* <strong>ç»„è›‹ç™½ä¿®é¥°ä¸åŸºå› ç»„ç»“åˆåˆ†æ</strong>ï¼šChIP-Seqå’ŒATAC-seqç­‰æŠ€æœ¯ç”¨äºè§£æç»„è›‹ç™½ä¿®é¥°å’ŒæŸ“è‰²è´¨å¯åŠæ€§å¯¹åŸºå› è¡¨è¾¾åŠç»†èƒåŠŸèƒ½çš„å½±å“ã€‚</p>
<h3>ğŸ§ª åšå®¢æ›´æ–°</h3>
<blockquote>
<p><strong>ä»Šæ—¥ç„¦ç‚¹</strong>ï¼š<br />
æ–°å‹AIæ¡†æ¶CellAtriaé¦–æ¬¡å®ç°å•ç»†èƒRNAæµ‹åºæ•°æ®çš„è‡ªåŠ¨åŒ–ã€æ ‡å‡†åŒ–åˆ†æï¼Œå¤§å¹…æå‡å…¬å…±æ•°æ®é›†çš„å¯åŠæ€§ï¼›åŒæ—¶å‘ç°ç»´ç”Ÿç´ Aä»£è°¢äº§ç‰©èƒ½æŠ‘åˆ¶å…ç–«ç³»ç»Ÿï¼ŒåŠ©è‚¿ç˜¤é€ƒé¿å…ç–«æ”»å‡»ï¼Œå¹¶å·²å¼€å‘å‡ºé¶å‘è¯ç‰©ã€‚</p>
</blockquote>
<p><strong>ä¸»è¦æ–¹å‘</strong>ï¼š<br />
- è‡ªåŠ¨åŒ–å•ç»†èƒRNAæµ‹åºæ•°æ®åˆ†æä¸æ ‡å‡†åŒ–<br />
- ç»´ç”Ÿç´ Aä»£è°¢äº§ç‰©å¯¹è‚¿ç˜¤å…ç–«é€ƒé€¸çš„å½±å“åŠå…¶å¹²é¢„</p>
<p><strong>æŠ€æœ¯äº®ç‚¹</strong>ï¼š<br />
- åŸºäºAgentic AIçš„å•ç»†èƒæ•°æ®å¤„ç†æ¡†æ¶<br />
- é¶å‘ç»´ç”Ÿç´ Aä»£è°¢é€šè·¯ä»¥å¢å¼ºæŠ—è‚¿ç˜¤å…ç–«çš„è¯ç‰©å¼€å‘</p>
            </div><h2>ğŸ“š åˆ†ç±»æµè§ˆ</h2>
<details>
<summary style="text-align: right; direction: rtl; padding: 10px 15px; background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%); border-right: 4px solid #667eea; font-weight: 600; cursor: pointer; margin: 15px 0; border-radius: 6px;">ğŸ§¬ æ•°æ®å‰æ²¿ (40æ¡)</summary>
<div class="details-content">
<h4>è¯¦ç»†å†…å®¹ï¼ˆå‰10æ¡ï¼‰</h4>
<p><strong>1.</strong> â­ <strong>GSE316752 è‚¿ç˜¤ç»†èƒèšé›†é€šè¿‡è°ƒèŠ‚ H3K36 ç»„è›‹ç™½å»ç”²åŸºåŒ–é…¶ KDM2A å¢å¼ºè½¬ç§»èƒ½åŠ› [ChIP-Seq]</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼štumorã€ChIP-seqã€histoneã€clustering<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Carolyn Kravitz ; Kiran D Patel ; Emily Wingrove ; Dejian Zhao ; Tang Tang ; Sampada Chande ; Yuchen Huo ; Thomas F Westbrook ; Qin Yan ; Don X NguyenSeries Type : Genome binding/occupancy profiling by high throughput sequencingOrganism : Homo sapiensDisseminated tumor cells can form clusters via cell-cell adhesion, which increases their capacity to initiate metastasis. Metastatic clusters are characterized by distinct changes in transcription, suggesting that epigenetic mechanisms underlie their unique phenotypic state. By performingfunctional epigenomic studies in models of non-small-cell lung cancer, we identified the histone H3 lysine 36 (H3K36) demethylase KDM2A as being differentially required for the fitness of metastatic cell clusters. This contextual dependency on KDM2A is predicated by tumor cell-cell aggregation, which specifically induces KDM2A binding to CpG island enriched promoters. At these defined genomic loci, KDM2A maintains H3K36 monomethylation, which preferentially correlates with transcriptional activation. KDM2A directly targets oxidative phosphorylation genes and KDM2A activity is required for optimal mitochondrial respiration and apical cell junction integrity in cell clusters. Consequently, suppressing KDM2A reduces metastatic seeding and colonization in multiple organs, including in the brain. These findings reveal a chromatin regulatory mechanism by which homotypic cell communication instructs the epigenome of disseminated tumor cells to potentiate their metastatic competence.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE316752" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>2.</strong> â­ <strong>GSE316191 é¶å‘ HMGB2 å¯ä½œä¸ºåŒé‡å…ç–«è°ƒèŠ‚å‰‚ï¼Œé€šè¿‡å¢å¼º CD8+ T ç»†èƒåŠŸèƒ½å’ŒæŠ‘åˆ¶è‚ç»†èƒç™Œçš„è‚¿ç˜¤ç”Ÿé•¿å‘æŒ¥ä½œç”¨ [ATAC-seq]</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼štumorã€carcinomaã€T cellã€ATAC-seq<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Weifeng Qu ; Guiqi Zhu ; Yinghong ShiSeries Type : Genome binding/occupancy profiling by high throughput sequencingOrganism : Mus musculusT cell exhaustion is a critical obstacle for durable treatment response in hepatocellular carcinoma (HCC). Developing drugs that control tumor growth and simultaneously bolster immune function is of great significance. The transcriptional regulator high mobility group box 2 (HMGB2) has emerged as a risk factor in prognosis of HCC. However, the role of HMGB2 in HCC tumor microenvironment (TME) is poorly understood. Here, we discovered HMGB2+ CD8+ T cells as being associated with T cell exhaustion and resistance to anti-PD-1 treatment through single-cell RNA sequencing of human and murine HCC tissues. Mechanistically, HMGB2 impaired the mitochondrial oxidative phosphorylation in CD8+ T cells by increasing the ubiquitination of NRF2, thus reduced the antitumor effector function. In tumor cells, HMGB2 inactivated the interferon-Î³ (IFN-Î³) response through TRIM24/STAT1 pathway, inhibiting susceptibility and recruitment to effector T cells. Tannic acid, a specific inhibitor of HMGB2, synergized with PD-1 antibody to attenuate tumor growth and reverse T cell exhaustion. Collectively, this study revealed that HMGB2, a T cell exhaustion associated molecule, contributed to tumor immune escape by dual action on CD8+ T cells and tumor cells. These data also provided translational insight into synergistic treatment strategies.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE316191" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>3.</strong> â­ <strong>GSE315942 æŸ“è‰²ä½“ä¸ç¨³å®šæ€§é€šè¿‡ cGASâ€“è¶‹åŒ–å› å­â€“é«“ç³»è½´å¡‘é€ é£Ÿç®¡è…ºç™Œçš„è‚¿ç˜¤å¾®ç¯å¢ƒ [RNA-seq]</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼štumorã€tumor microenvironmentã€chemokineã€RNA-seq<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Bruno Beernaert ; Eileen E ParkesSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensChromosomal instability (CIN), a pervasive feature of esophageal adenocarcinoma (EAC), drives tumor aggressiveness and metastasis. CIN stimulates the cGASâ€“STING pathway, typically linked to anti-tumor immunity. However, despite the high CIN burden in EAC, the cGASâ€“STING pathway remains largely intact. To address this paradox, we interrogated multiple esophageal cancer models, discovering myeloid-attracting chemokines â€“ with CXCL8 as a prominent hit â€“ as conserved CIN-driven targets in EAC. Using multiplexed immunofluorescence microscopy, we quantified ongoing CIN in human EAC tumors by measuring cGAS-positive micronuclei, validated by whole-genome sequencing. Coupling in situ CIN detection with single-nucleus RNA sequencing and multiplex immunophenotyping of human EAC, we link CIN to tumor-intrinsic innate immune activation, CXCL8 expression, and myeloid cell-mediated immunosuppression. In EAC patients, CIN-high, myeloid-dominated tumors correlate with poor outcomes and aberrant cGASâ€“STING signaling. These insights explain the counterintuitive maintenance of cGASâ€“STING and highlight disruption of the CINâ€“cGASâ€“inflammation axis as a potential therapeutic strategy in EAC.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE315942" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>4.</strong> â­ <strong>GSE316655 Claudins ä¸ LILRB å…ç–«æŠ‘åˆ¶å—ä½“ç›¸äº’ä½œç”¨ï¼Œä¿ƒè¿›ç™Œç—‡ä¸­çš„é«“ç³»å…ç–«æŠ‘åˆ¶</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šcancerã€immuneã€regex:immuno(logy|therapy|suppression)<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Xiaoye Liu ; Alec Zhang ; Kenian ChenSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensThe mechanisms underlying tumor cell-myeloid cell interactions within the tumor microenvironment (TME) remain unclear, and predictive biomarkers for patient response to myeloid checkpoint blockade are lacking. This study identified specific binding between tight-junction claudins (CLDNs) and leukocyte immunoglobulin-like receptor subfamily B members LILRB2 and LILRB5. In multiple human cancer cohorts, the spatial proximity of LILRB2âº macrophages to CLDN-expressing cancer cells correlated with clinical outcomes, nominating this spatial relationship as a potential biomarker. In syngeneic LILRB2-transgenic and humanized mouse models, CLDN18.2â€“LILRB2 interaction triggered bidirectional signaling, enhanced the immunosuppressive activity of myeloid cells, and accelerated tumor progression. These effects were reversed by LILRB2 blockade. Mechanistically, the CLDN-LILRB2 axis sustained immunosuppression by regulating NF-ÎºB and STAT signaling pathways. Our findings reveal a novel tight junction protein-mediated mechanism of myeloid cell regulation in the TME, offering a rationale for targeting this pathway in cancer therapy.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE316655" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>5.</strong> â­ <strong>GSE316127 æŸ“è‰²ä½“ä¸ç¨³å®šæ€§é€šè¿‡ cGAS-è¶‹åŒ–å› å­-é«“ç³»è½´å¡‘é€ é£Ÿç®¡è…ºç™Œçš„è‚¿ç˜¤å¾®ç¯å¢ƒ</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼štumorã€tumor microenvironmentã€chemokine<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Bruno Beernaert ; Eileen E ParkesSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensChromosomal instability (CIN), a pervasive feature of esophageal adenocarcinoma (EAC), drives tumor aggressiveness and metastasis. CIN stimulates the cGASâ€“STING pathway, typically linked to anti-tumor immunity. However, despite the high CIN burden in EAC, the cGASâ€“STING pathway remains largely intact. To address this paradox, we interrogated multiple esophageal cancer models, discovering myeloid-attracting chemokines â€“ with CXCL8 as a prominent hit â€“ as conserved CIN-driven targets in EAC. Using multiplexed immunofluorescence microscopy, we quantified ongoing CIN in human EAC tumors by measuring cGAS-positive micronuclei, validated by whole-genome sequencing. Coupling in situ CIN detection with single-nucleus RNA sequencing and multiplex immunophenotyping of human EAC, we link CIN to tumor-intrinsic innate immune activation, CXCL8 expression, and myeloid cell-mediated immunosuppression. In EAC patients, CIN-high, myeloid-dominated tumors correlate with poor outcomes and aberrant cGASâ€“STING signaling. These insights explain the counterintuitive maintenance of cGASâ€“STING and highlight disruption of the CINâ€“cGASâ€“inflammation axis as a potential therapeutic strategy in EAC.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE316127" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>6.</strong> â­ <strong>GSE316062 æŸ“è‰²ä½“ä¸ç¨³å®šæ€§é€šè¿‡ cGASâ€“è¶‹åŒ–å› å­â€“é«“ç³»è½´å¡‘é€ é£Ÿç®¡è…ºç™Œçš„è‚¿ç˜¤å¾®ç¯å¢ƒ [snRNA-Seq]</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼štumorã€tumor microenvironmentã€chemokine<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Bruno Beernaert ; Eileen E ParkesSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensChromosomal instability (CIN), a pervasive feature of esophageal adenocarcinoma (EAC), drives tumor aggressiveness and metastasis. CIN stimulates the cGASâ€“STING pathway, typically linked to anti-tumor immunity. However, despite the high CIN burden in EAC, the cGASâ€“STING pathway remains largely intact. To address this paradox, we interrogated multiple esophageal cancer models, discovering myeloid-attracting chemokines â€“ with CXCL8 as a prominent hit â€“ as conserved CIN-driven targets in EAC. Using multiplexed immunofluorescence microscopy, we quantified ongoing CIN in human EAC tumors by measuring cGAS-positive micronuclei, validated by whole-genome sequencing. Coupling in situ CIN detection with single-nucleus RNA sequencing and multiplex immunophenotyping of human EAC, we link CIN to tumor-intrinsic innate immune activation, CXCL8 expression, and myeloid cell-mediated immunosuppression. In EAC patients, CIN-high, myeloid-dominated tumors correlate with poor outcomes and aberrant cGASâ€“STING signaling. These insights explain the counterintuitive maintenance of cGASâ€“STING and highlight disruption of the CINâ€“cGASâ€“inflammation axis as a potential therapeutic strategy in EAC.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE316062" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>7.</strong> <strong>GSE316732 é›·å¸•éœ‰ç´ é€†è½¬è‚è„å¯¹é¥®é£Ÿè¯±å¯¼çš„ä»£è°¢åº”æ¿€çš„ååº”ï¼Œè¿™ç§ååº”ä¼šéšç€å¹´é¾„çš„å¢é•¿è€ŒåŠ å‰§ã€‚</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šagingã€metabolic<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Aaron P. Havas ; Adarsh Rajesh ; Xue Lei ; Peter D. AdamsSeries Type : Expression profiling by high throughput sequencingOrganism : Mus musculusAging is associated with increased susceptibility to metabolic stress and chronic liver disease, yet the interactions between age and metabolic stressors and the potential for ameliorating interventions remain incompletely understood. Here, we examined the hepatic response of young (7-month-old) and old (25-month-old) C57BL/6 male mice to a 9-week high-fat diet (HFD) and assessed whether rapamycin, a well-established pro-longevity intervention, could mitigate age-exacerbated effects. While both age groups developed metabolic-associated steatohepatitis (MASH), older mice displayed more severe hepatic steatosis, inflammation, and transcriptional dysregulation. Transcriptomic profiling of whole livers and purified hepatocytes revealed that aging amplifies HFD-induced inflammatory and metabolic gene expression changes, including activation of immune pathways and suppression of metabolic pathways. Notably, treatment of aging mice with rapamycin reversed the majority of HFD-driven transcriptional alterations, including upregulation of pro-inflammatory regulators such as Stat1, and dysregulation of metabolic gene networks. Rapamycin also reduced hepatosteatosis, total body weight, and a tumorigenic transcriptomic signature associated with hepatocellular carcinoma risk. These findings demonstrate that aging intensifies hepatic sensitivity to dietary metabolic stress and identify rapamycin as a promising therapeutic to counteract age-related liver dysfunction and metabolic dysfunction-associated steatotic liver disease (MASLD) progression.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE316732" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>8.</strong> <strong>GSE291910 Dnmt3a ä¾èµ–çš„ä»å¤´ DNA ç”²åŸºåŒ–å¢å¼ºè°±ç³»å®šå‘å¹¶ä¿æŒè®°å¿† Th1 å’Œ Tfh ç»†èƒçš„åŠŸèƒ½ [RNA-seq]</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šRNA-seqã€methylation<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Scott Hale ; Bryant PerkinsSeries Type : Expression profiling by high throughput sequencingOrganism : Mus musculusFollowing acute viral infection, naÃ¯ve CD4+ T cells differentiate into T follicular helper (Tfh) and T helper 1 (Th1) cells that generate long-lived memory cells. However, it is unclear how memory Tfh and Th1 cells maintain their lineage commitment. We demonstrate that Tfh and Th1 lineages acquire distinct Dnmt3a-dependent de novo DNA methylation programs that are preserved into memory. Dnmt3a deletion impairs lineage commitment and functionality of memory Th1 and Tfh cells, resulting in aberrant Runx1 upregulation that represses germinal center Tfh cell differentiation. In contrast, transient pharmacological DNA methyltransferase inhibition during priming impairs repression of Tfh-associated genes while properly silencing Runx1, and results in enhanced Tfh cell functionality in primary and secondary responses to viral infections. Together, these findings demonstrate that Dnmt3a-mediated epigenetic programing is required to enforce T helper lineage commitment and preserve Tfh and Th1-specific functions during the recall response to infection, and reveal novel strategies to improve long-lived adaptive immunity against infectious diseases.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE291910" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>9.</strong> <strong>GSE270117 7ç§PDAç»†èƒç³»çš„å•ç»†èƒRNAæµ‹åº</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šsequencingã€single-cell<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Pasquale Laise ; Mikko Turunen ; Alvaro C Garcia ; Lorenzo Tomassoni ; H C Maurer ; Ela Elyada ; Bernhard Schmierer ; Jeremy Worley ; Jordan Kesner ; Xiangtian Tan ; Ester C Fernandez ; Xue Yuanqing ; Chen Yining ; Kelly Wong ; Urszula N Wasko ; Somnath Tagore ; Alexander L Wang ; Sabrina Ge ; Alina C Iuga ; Aaron Griffin ; Winston Wong ; Gulam A Manji ; Mariano J Alvarez ; Faiyaz Notta ; David A Tuveson ; Kenneth P Olive ; Andrea CalifanoSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensWe performed Single-Cell RNA Sequencing of 7 PDA Cell Lines to characterize and quantify PDA subtypes populations<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE270117" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>10.</strong> <strong>GSE159921 æ··åˆè½¬å½•å› å­è¿‡è¡¨è¾¾åˆ†æï¼ˆå•ç»†èƒRNAæµ‹åºï¼‰</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šRNAseqã€single-cell<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Pasquale Laise ; Mikko Turunen ; Alvaro C Garcia ; Lorenzo Tomassoni ; H C Maurer ; Ela Elyada ; Bernhard Schmierer ; Jeremy Worley ; Jordan Kesner ; Xiangtian Tan ; Ester C Fernandez ; Sue Yuanqing ; Chen Yining ; Kelly Wong ; Urszula N Wasko ; Somnath Tagore ; Alexander L Wang ; Sabrina Ge ; Alina C Iuga ; Aaron Griffin ; Winston Wong ; Gulam A Manji ; Mariano J Alvarez ; Faiyaz Notta ; David A Tuveson ; Kenneth P Olive ; Andrea CalifanoSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensThe aim of this study is to investigate the effect of the combinatorial overexpression of the top GLS MRs in a MOS cell line (at single-cell level).<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE159921" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<blockquote>
<p>ğŸ’¡ è¯¥æ¥æºè¿˜æœ‰ 30 æ¡å†…å®¹ï¼Œè¯¦è§ <a href="#æ›´å¤š-æ•°æ®å‰æ²¿">æ–‡æœ«</a></p>
</blockquote>
</div>
</details>

<details>
<summary style="text-align: right; direction: rtl; padding: 10px 15px; background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%); border-right: 4px solid #667eea; font-weight: 600; cursor: pointer; margin: 15px 0; border-radius: 6px;">ğŸ§ª åšå®¢æ›´æ–° (2æ¡)</summary>
<div class="details-content">
<h4>è¯¦ç»†å†…å®¹ï¼ˆå…¨éƒ¨2æ¡ï¼‰</h4>
<p><strong>1.</strong> <strong>ç”¨äºå•ç»†èƒRNAæµ‹åºæ•°æ®åˆ†ææ‘„å–å’Œæ ‡å‡†åŒ–çš„æ™ºèƒ½ä½“AIæ¡†æ¶</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šRNA-seqã€single-cell<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šCellAtria uses AI to automate data ingestion and RNA sequencing analysis, making reuse of public single-cell datasets faster, standardized, and accessible without advanced computational skills...<br />
- ğŸ”— <a href="https://www.rna-seqblog.com/an-agentic-ai-framework-for-ingestion-and-standardization-of-single-cell-rna-seq-data-analysis/" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>2.</strong> <strong>ç»´ç”Ÿç´ Aå¯èƒ½æœ‰åŠ©äºç™Œç»†èƒèº²é¿å…ç–«ç³»ç»Ÿçš„æ”»å‡»ã€‚</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šcancerã€immune<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šA vitamin A byproduct has been found to quietly disarm the immune system, allowing tumors to evade attack and weakening cancer vaccines. Scientists have now developed a drug that shuts down this pathway, dramatically boosting immune responses and slowing cancer growth in preclinical studies.<br />
- ğŸ”— <a href="https://www.sciencedaily.com/releases/2026/01/260115022808.htm" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
</div>
</details>

<h2>ğŸ“Š å…³é”®è¯ç»Ÿè®¡</h2>
<table class="keywords-table">
<thead>
<tr>
<th>å…³é”®è¯</th>
<th>å‡ºç°æ¬¡æ•°</th>
</tr>
</thead>
<tbody>
<tr>
<td>single-cell</td>
<td>8</td>
</tr>
<tr>
<td>RNA-seq</td>
<td>6</td>
</tr>
<tr>
<td>tumor</td>
<td>6</td>
</tr>
<tr>
<td>cancer</td>
<td>5</td>
</tr>
<tr>
<td>sequencing</td>
<td>5</td>
</tr>
<tr>
<td>methylation</td>
<td>4</td>
</tr>
<tr>
<td>immune</td>
<td>3</td>
</tr>
<tr>
<td>tumor microenvironment</td>
<td>3</td>
</tr>
<tr>
<td>chemokine</td>
<td>3</td>
</tr>
<tr>
<td>aging</td>
<td>2</td>
</tr>
<tr>
<td>metabolic</td>
<td>2</td>
</tr>
<tr>
<td>ChIP-seq</td>
<td>1</td>
</tr>
<tr>
<td>histone</td>
<td>1</td>
</tr>
<tr>
<td>clustering</td>
<td>1</td>
</tr>
<tr>
<td>regex:immuno(logy</td>
<td>therapy</td>
</tr>
<tr>
<td>carcinoma</td>
<td>1</td>
</tr>
<tr>
<td>T cell</td>
<td>1</td>
</tr>
<tr>
<td>ATAC-seq</td>
<td>1</td>
</tr>
<tr>
<td>genome</td>
<td>1</td>
</tr>
<tr>
<td>scRNA</td>
<td>1</td>
</tr>
</tbody>
</table>
<hr />
<h2>ğŸ“ æ›´å¤šå†…å®¹</h2>
<details>
<summary><a name="æ›´å¤š-æ•°æ®å‰æ²¿"></a>ğŸ§¬ æ•°æ®å‰æ²¿ å…¶ä»–å†…å®¹ (30æ¡)</summary>
<div class="details-content">
<ul>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE316818" target="_blank" rel="noopener noreferrer">GSE316818 ä¸€ç§ç»†èŒYopJå®¶æ—ä¹™é…°è½¬ç§»é…¶é€šè¿‡JAK1çš„NÎµ-ä¹™é…°åŒ–æŠ‘åˆ¶å®¿ä¸»å…ç–«ååº”</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE291819" target="_blank" rel="noopener noreferrer">GSE291819 å•ç»†èƒ RNA è½¬å½•ç»„æ­ç¤ºäº†æ°¯æ²™å¦å‡è½»æ°®èŠ¥è¯±å¯¼çš„è§’è†œæŸä¼¤çš„æ½œåœ¨æœºåˆ¶</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE316749" target="_blank" rel="noopener noreferrer">GSE316749 AURKA/PHB2 ä¿¡å·é€šè·¯é©±åŠ¨ KRAS G12C çªå˜å‹éå°ç»†èƒè‚ºç™Œå¯¹ KRAS G12C æŠ‘åˆ¶å‰‚äº§ç”Ÿè·å¾—æ€§è€è¯</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE316223" target="_blank" rel="noopener noreferrer">GSE316223 Î±-çªè§¦æ ¸è›‹ç™½ä»è‚ é“æ‰©æ•£è‡³å¤§è„‘çš„ä½“å†…æ¨¡å‹</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE287470" target="_blank" rel="noopener noreferrer">GSE287470 ç–¾ç—…ç›¸å…³å°èƒ¶è´¨ç»†èƒ TLR4-Lyn æ¿€é…¶æ˜¯ 5XFAD å°é¼ æ¨¡å‹ä¸­ç¥ç»ç‚ç—‡ã€AÎ² åå™¬ä½œç”¨ã€ç¥ç»å…ƒæŸä¼¤å’Œç»†èƒå­˜æ´»çš„å…³é”®è°ƒèŠ‚å› å­ã€‚</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE316754" target="_blank" rel="noopener noreferrer">GSE316754 è¡°è€ç»†èƒæ¸…é™¤ç–—æ³•å¢å¼ºå‰åˆ—è…ºç™ŒåŒ–ç–—çš„å…ç–«åŸæ€§</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE315021" target="_blank" rel="noopener noreferrer">GSE315021 åˆ©ç”¨DAP-SeqæŠ€æœ¯åˆ†æè½¬å½•å› å­RGSV P3çš„å…¨åŸºå› ç»„ç»“åˆä½ç‚¹</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE313496" target="_blank" rel="noopener noreferrer">GSE313496 å¤šç»„ç»‡ DNA ç”²åŸºåŒ–åˆ†æï¼Œæ—¨åœ¨è¯†åˆ«è„ŠæŸ±è£‚ç‰¹æœ‰çš„ç‹¬ç‰¹ç¥ç»ç»„ç»‡çš„åˆé€‚æ›¿ä»£ç»„ç»‡</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE277649" target="_blank" rel="noopener noreferrer">GSE277649 ç¼ºä¹ PD-1 çš„å¹²ç»†èƒæ · CD8+ T ç»†èƒé€šè¿‡é™ä½ TCR ä¿¡å·ä¼ å¯¼å’Œè‡ªæˆ‘æ›´æ–°èƒ½åŠ›æ¥é€‚åº”æ…¢æ€§åˆºæ¿€ [scRNA-seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE277648" target="_blank" rel="noopener noreferrer">GSE277648 ç¼ºä¹ PD-1 çš„å¹²ç»†èƒæ · CD8+ T ç»†èƒé€šè¿‡é™ä½ TCR ä¿¡å·ä¼ å¯¼å’Œè‡ªæˆ‘æ›´æ–°èƒ½åŠ›æ¥é€‚åº”æ…¢æ€§åˆºæ¿€ [RNA-seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE310584" target="_blank" rel="noopener noreferrer">GSE310584 äººç±» PDA ç»†èƒç³»ï¼šç»æ›²ç¾æ›¿å°¼ (TRAM) å’Œ/æˆ–ç¾Ÿæ°¯å–¹ (HCQ) æ²»ç–—åçš„å•ç»†èƒ RNA æµ‹åº</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE303670" target="_blank" rel="noopener noreferrer">GSE303670 æé«˜è‚¾ç§»æ¤ä¸­DSAé˜´æ€§æŠ—ä½“ä»‹å¯¼æ’æ–¥ååº”çš„ç»„ç»‡å­¦æ£€æµ‹</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE302604" target="_blank" rel="noopener noreferrer">GSE302604 æ…¢æ€§é—´æ­‡æ€§ä½æ°§æ¨¡æ‹Ÿç¡çœ å‘¼å¸æš‚åœï¼Œé‡å¡‘è‚è„æ˜¼å¤œä»£è°¢ç»“æ„</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE292402" target="_blank" rel="noopener noreferrer">GSE292402 ä½¿ç”¨ KP4 PDA ç»†èƒç³»è¿›è¡Œå•ç»†èƒæ¡å½¢ç è°±ç³»è¿½è¸ª - æ›²ç¾æ›¿å°¼è¯ç‰©æ²»ç–—å‰å</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE291914" target="_blank" rel="noopener noreferrer">GSE291914 Dnmt3aä¾èµ–çš„ä»å¤´DNAç”²åŸºåŒ–å¢å¼ºè°±ç³»å®šå‘å¹¶ç»´æŒè®°å¿†æ€§Th1å’ŒTfhç»†èƒçš„åŠŸèƒ½</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE291911" target="_blank" rel="noopener noreferrer">GSE291911 Dnmt3a ä¾èµ–çš„ä»å¤´ DNA ç”²åŸºåŒ–å¢å¼ºè°±ç³»å®šå‘å¹¶ä¿æŒè®°å¿† Th1 å’Œ Tfh ç»†èƒçš„åŠŸèƒ½ [WGEM-seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE288771" target="_blank" rel="noopener noreferrer">GSE288771 OCI-AML3 ä¸­ LTR12C å®¶æ—çš„è¡¨è§‚é—ä¼ æ²‰é»˜</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE280160" target="_blank" rel="noopener noreferrer">GSE280160 ä½“å¤–é˜µåˆ— OVOL2 åœ¨ PDA ç»†èƒç³»ä¸­çš„è¿‡è¡¨è¾¾ï¼ˆæ‰¹é‡ RNA-Seqï¼‰</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE268441" target="_blank" rel="noopener noreferrer">GSE268441 PATU8988S PDA ç»†èƒç³»å•ç»†èƒæ¡å½¢ç è°±ç³»è¿½è¸ª</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE268229" target="_blank" rel="noopener noreferrer">GSE268229 KP4 PDA ç»†èƒç³»å•ç»†èƒæ¡å½¢ç è°±ç³»è¿½è¸ª</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE268077" target="_blank" rel="noopener noreferrer">GSE268077 HS766T PDA ç»†èƒç³»å•ç»†èƒæ¡å½¢ç è°±ç³»è¿½è¸ª</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE266034" target="_blank" rel="noopener noreferrer">GSE266034 äººç±»èƒ°è…ºå¯¼ç®¡è…ºç™Œç»†èƒç³»ï¼šæ­£å¸¸åŸ¹å…»åŸºä¸æ— è¡€æ¸…åŸ¹å…»åŸºä¸­çš„å•ç»†èƒRNAæµ‹åº</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE161369" target="_blank" rel="noopener noreferrer">GSE161369 èƒ°è…ºç™Œæ•°æ®é›†</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE161368" target="_blank" rel="noopener noreferrer">GSE161368 TF è¿‡è¡¨è¾¾åˆ†æåœ¨ PDA ç»†èƒç³»ä¸­ï¼ˆæ‰¹é‡ RNA-Seqï¼‰</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE160977" target="_blank" rel="noopener noreferrer">GSE160977 æ¥è‡ª PDAC è‚¿ç˜¤æ‚£è€…æ¥æºå¼‚ç§ç§»æ¤æ¨¡å‹çš„å•ç»†èƒæ•°æ®ã€‚</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE159918" target="_blank" rel="noopener noreferrer">GSE159918 å…­ä¸ª PDA ç»†èƒç³»çš„æµ‹åºæ•°æ®ã€‚</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE316547" target="_blank" rel="noopener noreferrer">GSE316547 é€‰æ‹©æ€§è°ƒèŠ‚å°é¼ è‚ é“M1å’ŒM3æ¯’è•ˆç¢±å—ä½“è¡¨è¾¾å¯¹ç‰¹åŒ–ä¸Šçš®ç»†èƒå’Œä½“é‡å…·æœ‰ä¸åŒçš„å½±å“</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE313846" target="_blank" rel="noopener noreferrer">GSE313846 Notch1èƒå†…ç»“æ„åŸŸï¼ˆNICD1ï¼‰çš„ChIPæµ‹åºåˆ†æ</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE308855" target="_blank" rel="noopener noreferrer">GSE308855 æ•´åˆå¤šç»„å­¦åˆ†ææ­ç¤ºå¾®ç¯å¢ƒé‡å¡‘æ˜¯å±‹å°˜è¨è¯±å‘è‚ºç™Œè¿›å±•çš„å…³é”®é©±åŠ¨å› ç´ </a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE223225" target="_blank" rel="noopener noreferrer">GSE223225 äººç±»æˆçº¤ç»´ç»†èƒè¡°è€è¿‡ç¨‹ä¸­åŠŸèƒ½æ€§é•¿é“¾éç¼–ç RNAçš„é‰´å®šå’Œè¡¨å¾</a></li>
</ul>
</div>
</details>

<hr />
<p><em>ğŸ“… æŠ¥å‘Šç”Ÿæˆæ—¶é—´ï¼š2026-01-17 21:36</em><br />
<em>ğŸ¤– ç”± GitHub Actions è‡ªåŠ¨ç”Ÿæˆ</em></p>
    </div>
</body>
</html>